The Pharma Career Ladder · The country manager · Step 3: Money, pricing and forecast · Lesson 17

When to invest in a losing brand

Decide on what is ahead, not what is spent

By Ahmed El Menshawy · 20 years in pharma, from medical rep to country manager in the UAE. Founder of RepPharma. LinkedIn
Published

Every country has one.

The brand that has been "about to turn the corner" for several budget rounds.

When it comes up for review, the strongest argument in the room is rarely about the future. It is about the past. The launch spend. The years of effort. The people who built it.

"We have invested too much to stop now."

Kahneman writes about this as the sunk-cost fallacy. Money already spent feels like a reason to keep spending, even when it cannot be recovered whatever we decide.

In my experience, the better question is simpler: what can the next budget still earn?

To answer it honestly, I look forward, not back. The sell-out trend. The segments where the brand still has a real place. What doctors and pharmacists are actually telling the team.

And I ask someone outside the brand team to test the case. Not because the brand team is wrong, but because nobody judges their own work easily.

Sometimes the answer is to invest again, with clear milestones and a date to look again. Sometimes it is to stop, with a proper plan for customers and patients. Both are good decisions. Drifting is not.

“Money already spent should not vote on money not yet spent.”
When to invest in a losing brand: Decide on what is ahead, not what is spent

Lesson 17 of 17 in Step 3: Money, pricing and forecast, with the full guide and a checklist for this week.

More lessons in step 3: Money, pricing and forecast

Money, pricing and forecast, in RepPharma

Targets split by rep, product and month

Yearly targets are split by rep, product and month, and sales credit can be moved between reps without changing the company total.

Distributor stock and sell-out

Distributor stock and pharmacy sell-out side by side, with short-expiry lots flagged up to 90 days ahead.

One system for the whole field force

Visits, plans, forecasts, samples, expenses, leaves and approvals, with role-based access from rep to country manager.

A new step every week in the Pharma Career Ladder newsletter on LinkedIn.